Clinical outcomes in cancer patients with immune checkpoint inhibitor-induced arthritis treated with methotrexate: a retrospective longitudinal monocentric pilot study
The use of MTX in ICI-induced arthritis showed promising results in reducing GC dosages and managing the inflammatory articular activity, with no major toxicities observed over one year. These findings suggest that MTX may be a viable GC-sparing option in this context, but larger, controlled studies are needed to confirm these observations and better understand the impact on both articular and oncologic outcomes.
Authors
- Emanuele Gotelli (ORCID: https://orcid.org/0000-0002-4732-0306)
- Enrica T. Tanda (ORCID: https://orcid.org/0000-0002-1552-9826)
- Alberto Sulli (ORCID: https://orcid.org/0000-0003-3674-4880)
- Elvis Hysa (ORCID: https://orcid.org/0000-0002-6970-0983)
- Andrea Casabella (ORCID: https://orcid.org/0000-0002-1406-0114)
- Vanessa Smith
- Sabrina Paolino (ORCID: https://orcid.org/0000-0001-9269-5089)
- Carlo Genova (ORCID: https://orcid.org/0000-0003-3690-8582)
- Carmen Pizzorni (ORCID: https://orcid.org/0000-0001-5125-0200)
- Maurizio Cutolo (ORCID: https://orcid.org/0000-0002-4548-5334)
- Nicola Iandolino
Institutions
- VIB-UGent Center for Inflammation Research (BE)
- Rheumatology Consultants (US)
- Ospedale Policlinico San Martino (IT)
- Center for Rheumatology (US)
- University of Genoa (IT)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2024-11-01
- DOI
- https://doi.org/10.55563/clinexprheumatol/e49am5
- Citations
- 4
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.75
Funders
- Fonds Wetenschappelijk Onderzoek
- Vlaamse regering